(Q37264407)

19 August 2017

1 reference

title

Urological implications of cyclophosphamide and ifosfamide (English)

1 reference

19 August 2017

Malcolm Lawson

1

1 reference

19 August 2017

Arthur Vasilaras

2

1 reference

19 August 2017

Annamarie De Vries

3

1 reference

19 August 2017

Peter Mactaggart

4

1 reference

19 August 2017

David Nicol

5

1 reference

19 August 2017

1 January 2008

1 reference

Scandinavian Journal of Urology and Nephrology

19 August 2017

1 reference

19 August 2017

42

1 reference

19 August 2017

309-317

1 reference

19 August 2017

4

1 reference

Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics

19 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Metabolism and transport of oxazaphosphorines and the clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Metabolism of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Ifosfamide clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

High dose cyclophosphamide treatment for autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Optimisation of cyclophosphamide therapy in systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Treatment of lupus nephritis: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide and other new agents for the treatment of severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Metabolism and pharmacokinetics of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Role of Ifosfamide in Cervical Cancer: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Ifosfamide in Pediatric Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

The role of ifosfamide in the treatment of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Ifosfamide: let's not end the honeymoon too soon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide toxicity. Characterising and avoiding the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Side Effects of Ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Carcinoma of the Urinary Bladder in Patients Receiving Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Leiomyosarcoma of Urinary Bladder Following Cyclophosphamide Therapy: Report of Two Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Prevention of cyclophosphamide-induced hemorrhagic cystitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Bk virus: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Protection against the toxicity of alkylating agents by thiols: The mechanism of protection and its relevance to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Use of mesna to prevent ifosfamide-induced urotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

21 January 2018

Mesna--a short review

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Combined intravenous and oral mesna in outpatients treated with ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide-induced hemorrhagic cystitis successfully treated with conjugated estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Ifosfamide, mesna, and nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Renal ontogeny of ifosfamide nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Chronic ifosfamide nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide and the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Urinary bladder carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Drug-induced bladder and urinary disorders. Incidence, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Carcinoma of the Urinary Bladder after Treatment with Cyclophosphamide for Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365590701570953

10.1080/00365590701570953

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference